The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

1987 • 2,788 citations

Expression of a multidrug-resistance gene in human tumors and tissues.

1987 • 1,547 citations

Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

1981 • 1,463 citations

Expression of Multidrug Resistance Gene in Human Cancers

1989 • 1,305 citations

Pharmacology of drugs that alter multidrug resistance in cancer.

1990 • 970 citations

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1989 • 565 citations

Cardiotoxicity of adriamycin and related anthracyclines

1976 • 377 citations

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

1991 • 364 citations

Modulation of multidrug-resistant multiple myeloma by cyclosporin

1992 • 317 citations

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

1992 • 298 citations

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

1993 • 284 citations

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

1992 • 221 citations

Expression of mdr1 and mdr3 Multidrug-resistance Genes in Human Acute and Chronic Leukemias and Association With Stimulation of Drug Accumulation by Cyclosporine

1990 • 210 citations

Function and Regulation of the Human Multidrug Resistance Gene

1992 • 186 citations

Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.

1977 • 166 citations

Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma

1986 • 147 citations

Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.

1988 • 124 citations

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

1992 • 108 citations

Efficacy and cost of cardiac monitoring in patients receiving doxorubicin

1982 • 94 citations

Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity.

1991 • 87 citations

Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts

1989 • 78 citations

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance

1991 • 72 citations

A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide

1992 • 60 citations

Phase I and pharmacokinetic study of D-verapamil and doxorubicin

1991 • 57 citations

Effects of Verapamil on the Acute Toxicity of Doxorubicin In Vivo

1992 • 48 citations

Enhancement of etoposide-induced cytotoxicity by cyclosporin A

1986 • 45 citations

Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study

1990 • 43 citations

Time-Course Study on Doxorubicin-Induced Nephropathy and Cardiomyopathy in Male and Female LOU/M/Wsl Rats: Lack of Evidence for a Causal Relationship

1986 • 27 citations

In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour

1993 • 19 citations

Effects of Verapamil on Chronic Doxorubicin-Induced Cardiotoxicity in Dogs

1990 • 13 citations

Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance.

1989 • 10 citations